? ? ? ?派安普利單抗，Penpulimab，CAS: 2350298-92-7，AntibodySystem Laboratories

　　貨號：DHH02225

　　產(chǎn)品鏈接：http://www.atagenix.com/product_detail-74831.html

　　別名：AK-105, CAS: 2350298-92-7

　　簡介：

　　派安普利單抗 Penpulimab 是一種 IgG1 抗 PD-1 單克隆抗體，具有抗腫瘤活性。

　　貨號：DHH02225

　　產(chǎn)品品牌：Antibodysystem

　　通用名：Penpulimab

　　純度：>95% by SDS-PAGE.

　　濃度：1mg/ml

　　Formulationicon：0.01M PBS, pH 7.4.

　　內(nèi)毒素：Please contact with the lab for this information.

　　別名：AK-105

　　靶點;物種：Human CD279/PDCD1/PD1

　　種類：Humanized

　　受體鑒定：IgG1-Kappa

　　CAS: 2350298-92-7

　　存儲條件：

　　Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

　　Store at +4°C short term (1-2 weeks).

　　Store at -20 °C 12 months.

　　Store at -80°C long term.

　　參考文獻(xiàn)：

　　Penpulimab: First Approval. PMID: 34813051

　　Antibodies to watch in 2022. PMID: 35030985

　　Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. PMID: 35165764

　　Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. PMID: 35833116

　　Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). PMID: 34327136

　　Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). PMID: 35875118

　　Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report. PMID: 36033531

　　Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1. PMID: 35503192

　　Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report. PMID: 35321433